deltatrials
Terminated PHASE2 NCT00162773

Effect of Anti-IgE in Non-Allergic Asthma

Sponsor: Genentech, Inc.

Conditions Asthma
Interventions Placebo omalizumab
Updated 6 times since 2017 Last updated: Jul 27, 2017 Started: Apr 30, 2005 Primary completion: Sep 30, 2009 Completion: Sep 30, 2009

Listed as NCT00162773, this PHASE2 trial focuses on Asthma and remains terminated or withdrawn. Sponsored by Genentech, Inc., it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Sep 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Unknown Status → Terminated

▶ Show 1 earlier version

  1. Jan 2017 — Sep 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Genentech, Inc.
  • Johns Hopkins University
Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Baltimore, United States